BioSpace News Archive

Rigel Pharmaceuticals, Inc. announced that it intends to offer and sell up to 15,000,000 shares of its common stock in an underwritten public offering.

City of Hope’s annual Kids 4 Hope program, in partnership with Albertsons Companies Foundation, Vons Foundation and Pavilions Foundation, has raised over $1 million to support research and treatment for pediatric cancers.

Pfenex Inc. and China NT Pharma Group Company Limited announced an agreement under which Pfenex granted NT Pharma non-exclusive development and exclusive commercialization rights to PF708, a teriparatide therapeutic equivalent candidate to Eli Lilly & Company’s Forteo®, in Mainland China, Hong Kong, Singapore, Malaysia and Thailand.

Arthrosurface® announced today that The Company received FDA 510(k) Clearance to market the OVOMotion™ Shoulder Arthroplasty System.

On the eve of the anniversary of the US Deepwater Horizon disaster, polluted beaches, oily water, dead birds and marine life destruction caused by crude oil spills could be a thing of the past thanks to pioneering research led by Flinders University.

Astellas Pharma Inc. and Kite announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite.

Performance and Age Management Medicine is pleased to announce they now offer GAINSWave!

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations (exon 19 deletions or exon 21 L858R mutations), as detected by an FDA-approved test.

Roche announced it has received approval from the U.S. Food and Drug Administration (FDA) of its Premarket Approval (PMA) supplement for the cobas® EGFR Mutation Test v2 to be used as a companion diagnostic test (CDx) with TAGRISSO® for first line treatment of patients diagnosed with metastatic NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations.

WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announced the opening of its expanded Laboratory Testing Division (LTD) facility in New Jersey.